{"id":"W2574859067","doi":"10.1182/blood.v124.21.1995.1995","title":"Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Fludarabine; Internal medicine; Cyclophosphamide; Gastroenterology; Chronic lymphocytic leukemia; CD20; Pharmacokinetics; Pharmacology; Urology; Chemotherapy; Leukemia; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154878,0.0005500391,0.001341846,0.0002182106,0.000152959,0.001070751,0.0004121808,0.0009274323,0.003020718],"category_scores_gemma":[0.001912052,0.0003448341,0.00114057,0.0002951777,0.0005503427,0.0006618185,0.000174077,0.002281095,0.0005423909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006232561,"about_ca_system_score_gemma":0.0007060912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004775025,"about_ca_topic_score_gemma":0.0009298088,"domain_scores_codex":[0.9991965,0.0004491348,0.0000398997,0.0001487926,0.00008395432,0.00008170694],"domain_scores_gemma":[0.9988027,0.0003502257,0.0004307864,0.0001227857,0.00005423915,0.0002392746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7077263,0.01393594,0.009908793,0.0009561231,0.002069631,0.0002483574,0.0002884084,0.003408657,0.1139416,0.0003777116,0.002617711,0.1445208],"study_design_scores_gemma":[0.2093856,0.7028846,0.04866884,0.00008396291,0.002502777,0.0006578153,0.0001492782,0.005249687,0.02413399,0.000528764,0.005686455,0.00006816164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949656,0.002033372,0.0007749397,0.0001975881,0.00005363864,0.0003855388,0.000423062,0.0000696968,0.001096645],"genre_scores_gemma":[0.9973367,0.0004666718,0.0005252713,0.000233625,0.00006309745,0.0001583043,0.0004168043,0.00002411842,0.0007752689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003020718,"threshold_uncertainty_score":0.01010525,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00815180799116277,"score_gpt":0.2675118212815842,"score_spread":0.2593600132904214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}